Celgene Corp. v. Biocon Pharma Ltd. et al.
settled- Court:
- D.N.J.
Celgene asserted the '800 and '217 patents against Biocon over lenalidomide ANDA products. The case settled.
Defendant
1 case as defendant.
Company overview. Biocon Pharma, Inc. is a Delaware corporation and the U.S. generic-formulations arm of the Biocon group. Per its corporate disclosure in a related case (Boehringer Ingelheim v. Biocon, D. Del.), Biocon Pharma, Inc. is a wholly owned subsidiary of Biocon Pharma Limited, which in turn is a wholly owned subsidiary of Biocon Limited, an Indian company incorporated in 1978 and headquartered in Bengaluru. Biocon Limited is publicly listed on the NSE (BIOCON) and BSE (532523); no shareholder holds more than 10%. Group headcount was reported around 16,000 (MarketScreener), with FY25 consolidated revenue of ₹164,699 million (~US$1.9 billion).
Products / operations. Biocon Limited is an operating biopharmaceuticals group with three segments: Generics (complex APIs and generic formulations, including statins, immunosuppressants, peptides/GLP-1s — 75+ APIs, 80+ formulations); Biosimilars, run by subsidiary Biocon Biologics (20-asset portfolio across oncology, diabetes, immunology and ophthalmology, sold in 120+ countries); and Research Services via listed subsidiary Syngene, a CRDMO. The Novel Biologics business was discontinued in December 2023. Biocon Pharma, Inc. is not an NPE — it operates as the U.S. generics/filings entity.
Patent-litigation posture. With one tracked case and zero plaintiff-side suits, Biocon Pharma, Inc. is a pure operating-company defendant: a generic filer sued by a brand pharmaceutical company. There is no evidence of patent assertion activity. The suit sits in the District of New Jersey, a standard venue for Hatch-Waxman ANDA disputes (not an EDTX-style NPE venue).
Notable case. Celgene Corp. v. Biocon Pharma Ltd. et al., No. 2:21-cv-11261 (D.N.J., filed May 14, 2021). Celgene alleged that Biocon's ANDA for generic REVLIMID (lenalidomide) would infringe its patents. Biocon answered and counterclaimed for invalidity. The parties subsequently entered a confidential settlement, according to Biocon's exchange filing. Celgene is now a wholly owned subsidiary of Bristol Myers Squibb.
Celgene asserted the '800 and '217 patents against Biocon over lenalidomide ANDA products. The case settled.